|
29 Jun 2011 - £11.4M Series B Financing |
 |
 |
 |
|
Wednesday, 29 June 2011 00:00 |
Prosonix Secures £11.4M Series B Financing
Prosonix is pleased to announce the successful conclusion of a £11.4M Series B financing round. The round was led by Ventech (Paris, France), with support from additional new Investor Gilde Healthcare Partners (Utrecht, Netherlands) and existing Investors including Entrepreneurs Fund (London, UK) Quest for Growth (Leuven, Belgium) and Solon Ventures (London, UK).
|
|
Last Updated on Friday, 03 February 2012 08:23 |
|
Prosonix Announce Strategic Partnership with Sterling |
|
|
|
|
Monday, 02 May 2011 00:00 |
Prosonix is delighted to announce the successful GMP commercial-isation of its world leading respiratory particle engineering technology at Sterling's FDA approved facilities in Perugia, Italy. This combines Prosonix acknowledged leadership in the particle engineering of complex respiratory products and Sterling's position as Europe's leading independent steroid producer. http://www.sterling.it/
|
|
Last Updated on Monday, 26 September 2011 22:05 |
|
Prosonix Announce Joint Patent with Chiesi |
|
|
|
|
Friday, 24 September 2010 00:00 |
Prosonix is delighted to announce the publication of a world patent application with Chiesi (Italy) where Graham Ruecroft and Dipesh Parikh are named as co-inventors. The application, published as WO/2010/097188, relates to the preparation and formulation of unique UMAX ® combination particles for use in pharmaceutical formulations for inhalation, wherein each particle comprises of a long acting beta 2 agonist (LABA) and an inhaled corticosteroid (ICS).
|
|
Last Updated on Monday, 26 September 2011 22:06 |
|
Prosonix Announce The Launch of Co-Crystal Service |
|
|
|
|
Tuesday, 31 August 2010 00:00 |
Prosonix is delighted to announce the launch of its new co-crystal development and processing service, aimed specifically at the manufacturing of pharmaceutical co-crystals suitable for use in inhaled and oral medicine, using its proprietary technologies to facilitate co-crystal production at any scale alongside controlled particle size distribution and high purity.
|
|
Last Updated on Monday, 26 September 2011 22:06 |
|
Prosonix Announce The Scale-Up Of UMAX technology |
|
|
|
|
Sunday, 04 April 2010 00:00 |
In just a short space of time since its launch Prosonix has successfully scaled up of the UMAX ® particle engineering technology. The scale-up has now been carried out on several APIs in cGMP facilities and importantly demonstrates a seamless transition from laboratory to commercial scale batches, with no loss of formulation performance, independent of delivery platform or device.
|
|
Last Updated on Monday, 26 September 2011 22:23 |
|
Prosonix CEO David Hipkiss talks to in-Pharma |
|
|
|
|
Wednesday, 17 March 2010 00:00 |
|
|
|
Last Updated on Monday, 26 September 2011 22:23 |
|
Prosonix Attains International Quality Approval |
|
|
|
|
Friday, 26 June 2009 08:02 |
Prosonix (Oxford, UK) is pleased to announce that it has achieved accreditation to the Quality Management standard ISO 9001:2008 following a recent audit of business systems and procedures by independent external auditors SGS (UK) Ltd.
|
|
Last Updated on Monday, 26 September 2011 22:23 |
|
Prosonix Announce The Launch Of UMAX technology |
|
|
|
|
Friday, 05 March 2010 00:00 |
Prosonix is pleased to announce the launch of its UMAX ® technology - an acronym for Ultrasound Mediated Amorphous to Crystalline transition - which is a new disruptive particle engineering technology set to revolutionise respiratory medicine. The proprietary technology has now been demonstrated on over 30 generic and novel drug molecules and combination products.
|
|
Last Updated on Monday, 26 September 2011 22:24 |
|
|
|
<< Start < Prev 1 2 3 Next > End >>
|
|
Page 1 of 3 |
